Abstract:Novel antibody-engineering approaches have enabled the development of targeted innate cell engagers which redirect innate immune cells to eliminate cancer or suppressive immune cells. These antibodies function through binding to surface antigens on target cells and engaging activating receptors on innate immune cells such as natural killer cells and macrophages. Although early innate cell engagers have shown promise in controlling various cancer types, several major challenges remain in the clinics, including high tumor heterogeneity, low tumor immunogenicity, and reduced efficacy in solid tumors. Here, we present a universal innate cell engager as part of a novel adaptor-based antibody platform. Our universal innate cell engager utilizes a two-step approach combining the power of an adaptor and an effector antibody. First, an Fc-silenced adaptor antibody comprising P329G LALA mutations is used to target the desired antigen in the tumor microenvironment. Then, as an effector antibody, a universal innate cell engager directed against the P329G mutation on the adaptor antibody is used. Innate immune cells are recruited by the universal innate cell engager through its active Fc, leading to antibody-dependent cellular cytotoxicity against the target cells. To maximize innate cell activation, the Fc portion of the universal innate cell engager can be glycoengineered for enhanced FcgRIII affinity.In vitro and in vivo assays showed that our universal innate cell engager is inducing innate immune cell activation and innate immune cell-mediated target cell killing when combined with different antigen-targeted adaptor antibodies. Ultimately, this approach may enable off-the-shelf personalization via combination of universal effector cell engagers and selected adaptor antibodies specific to the patient's tumor profile. Citation Format: Idil Hutter-Karakoc, Marlena Surowka, Diana Darowski, Christina Klaus, Claudia Ferrara Koller, Thomas Hofer, Anne Freimoser-Grundschober, Ekkehard Mössner, Stephane Leclair, Pablo Umana, Christian Munz, Maria Amann, Christian Klein. Recruiting innate immune cells universally: Development of a novel universal innate cell engager for cancer-immunotherapy [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr A054.

Polymer Micropatches as B-Cell Engagers

Polymer Micropatches as Natural Killer Cell Engagers for Tumor Therapy

Neutrophils bearing adhesive polymer micropatches as a drug-free cancer immunotherapy

Particle-Based Artificial Antigen-Presenting Cell Systems for T Cell Activation in Adoptive T Cell Therapy

Cutting Edge: Importance of IL-6 and Cooperation between Innate and Adaptive Immune Receptors in Cellular Vaccination with B Lymphocytes1

A general pHLA-CD80 scaffold fusion protein to promote efficient antigen-specific T cell-based immunotherapy

Surface‐Functionalized Microgels as Artificial Antigen‐Presenting Cells to Regulate Expansion of T Cells

Facile Transformation of Murine and Human Primary Dendritic Cells into Robust and Modular Artificial Antigen‐Presenting Systems by Intracellular Hydrogelation

Biomaterial Engineering Strategies for B Cell Immunity Modulations

A Bispecific Peptide-Polymer Conjugate Bridging Target-Effector Cells to Enhance Immunotherapy.

Multiantigen T-Cell Hybridizers: A Two-Component T-Cell-Activating Therapy

Combination of High-Resolution Structures for the B Cell Receptor and Co-Receptors Provides an Understanding of Their Interactions with Therapeutic Antibodies

In Situ Polymerization-Mediated Antigen Presentation

Combating bone marrow failure with polymer materials

Artificial Antigen-Presenting Cell Topology Dictates T Cell Activation

A novel system of artificial antigen-presenting cells efficiently stimulates Flu peptide-specific cytotoxic T cells in vitro.

Plasma cell biology: principles for therapeutic design

Approaches of the Innate Immune System to Ameliorate Adaptive Immunotherapy for B-Cell Non-Hodgkin Lymphoma in Their Microenvironment

Abstract A054: Recruiting innate immune cells universally: Development of a novel universal innate cell engager for cancer-immunotherapy

Dendritic Cell Immune Modulation via Polyphenol Membrane Coatings

Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds